We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CRVS market cap is 294.94M. The company's latest EPS is USD -0.4206 and P/E is -11.25.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.64M | -6.43M | -7.06M | -6.25M | -6.28M |
| Net Income | -6.5M | -6M | -6.65M | -5.7M | -4.26M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -48.85M | -43.99M | -43.46M | -42.57M | -28.69M |
| Net Income | -46.67M | -6M | -43.24M | -41.31M | -27.03M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 58.04M | 51.94M | 45.55M | 40.08M | 64.56M |
| Total Liabilities | 8.56M | 7.65M | 6.87M | 6.72M | 13.34M |
| Total Equity | 49.48M | 44.29M | 38.68M | 33.36M | 51.23M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 83.65M | 85.53M | 109.46M | 68.24M | 45.55M |
| Total Liabilities | 12.54M | 13.38M | 12.29M | 12.13M | 6.87M |
| Total Equity | 71.11M | 72.15M | 97.16M | 56.12M | 38.68M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -13.33M | -18.77M | -23.94M | -5.16M | -10.64M |
| Investing | 313k | 17.86M | 15.54M | -7k | -17.51M |
| Financing | 7.52M | 7.86M | 7.86M | N/A | 30.37M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -37.32M | -34.78M | -36.72M | -27.02M | -23.94M |
| Investing | 3.26M | 44.77M | 21.56M | -23.28M | 15.54M |
| Financing | 24k | 1.31M | 62.16M | N/A | 7.86M |
| Market Cap | 294.94M |
| Price to Earnings Ratio | -11.25 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 24.08 |
| Price to Book Ratio | 7.86 |
| Dividend Yield | - |
| Shares Outstanding | 64.26M |
| Average Volume (1 week) | 1.19M |
| Average Volume (1 Month) | 782.2k |
| 52 Week Change | 206.00% |
| 52 Week High | 10.00 |
| 52 Week Low | 1.30 |
| Spread (Intraday) | 0.21 (4.57%) |
| Company Name | Corvus Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.corvuspharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
